Small Gal-3 inhibitor, TD139, enhances production of reactive oxigen species in human neutrophils and ability of mice to clear the fungus, suggesting Gal-3 inhibition as a promising therapeutic strategy for treating systemic candidiasis (Wu et al., 2017). The gene discussed is LGALS3; the disease is candidiasis.